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ABSTRACT: The biotin−streptavidin technology has been
extensively exploited to engineer artiﬁcial metalloenzymes
(ArMs) that catalyze a dozen diﬀerent reactions. Despite its
versatility, the homotetrameric nature of streptavidin (Sav) and
the noncooperative binding of biotinylated cofactors impose
two limitations on the genetic optimization of ArMs: (i) point
mutations are reﬂected in all four subunits of Sav, and (ii) the
noncooperative binding of biotinylated cofactors to Sav may
lead to an erosion in the catalytic performance, depending on
the cofactor:biotin-binding site ratio. To address these
challenges, we report on our eﬀorts to engineer a (monovalent)
single-chain dimeric streptavidin (scdSav) as scaﬀold for Sav-
based ArMs. The versatility of scdSav as host protein is
highlighted for the asymmetric transfer hydrogenation of prochiral imines using [Cp*Ir(biot-p-L)Cl] as cofactor. By capitalizing
on a more precise genetic ﬁne-tuning of the biotin-binding vestibule, unrivaled levels of activity and selectivity were achieved for
the reduction of challenging prochiral imines. Comparison of the saturation kinetic data and X-ray structures of [Cp*Ir(biot-p-
L)Cl]·scdSav with a structurally related [Cp*Ir(biot-p-L)Cl]·monovalent scdSav highlights the advantages of the presence of a
single biotinylated cofactor precisely localized within the biotin-binding vestibule of the monovalent scdSav. The practicality of
scdSav-based ArMs was illustrated for the reduction of the salsolidine precursor (500 mM) to aﬀord (R)-salsolidine in 90% ee
and >17 000 TONs. Monovalent scdSav thus provides a versatile scaﬀold to evolve more eﬃcient ArMs for in vivo catalysis and
large-scale applications.
■ INTRODUCTION
Artiﬁcial metalloenzymes (ArMs) are hybrid catalysts combin-
ing attractive features of organometallic catalysts (e.g., broad
range of catalyzed reactions) and enzymes (e.g., genetically
evolvable and compatible with a cellular environment).1−12
They are often created by incorporation of a synthetic
metallocofactor within a protein scaﬀold. Thanks to the
progress in biotechnology, several scaﬀolds have proven
versatile for the assembly and optimization of ArMs. These
include, among others, hemeproteins,13−16 prolyl oligopepti-
dase,17,18 transcriptional repressor LmrR,19,20 carbonic anhy-
drase,21,22 and streptavidin (Sav).23,24 Due to the high aﬃnity
of biotin for (strept)avidin,25,26 this anchoring strategy had
been exploited by several groups to produce ArMs that catalyze
over a dozen reactions.27−36 As pioneered by Whitesides,
avidin (Avi) isolated from egg-white was initially selected. For
recombinant purposes, however, streptavidin (Sav) is preferred
thanks to the following features: (i) it can readily be expressed
in high yields in E. coli,37 (ii) it is less prone to aggregation, and
(iii) its isoelectric point pISav = 6.4 compared pIAvi = 10.4. Both
Avi and Sav are homotetrameric proteins consisting of a dimer
of dimers, where the two neighboring subunits are related by a
C2 axis. In the past 15 years, more than 20 X-ray structures of
Sav-based ArMs have been reported.9,24,31−34 Inspection of the
biotin-binding vestibule, where the catalytic moiety resides,
reveals a narrow distribution of biotinylated metals in the
immediate proximity of the C2 axis relating the two Sav
monomers that make up the biotin-binding vestibule, Figure
1a. Importantly, any point mutation is reﬂected in all four
subunits of homotetrameric Sav, Figure 1b. This symmetry-
relationship imposes a signiﬁcant limitation for the genetic
optimization of Sav-based ArMs. Indeed, inspection of the
biotin-binding vestibule (Figure 1a) highlights the proximity of
biotinylated cofactors to the two symmetry-related S112 and
K121 residues. Accordingly, any mutation of these residues is
reﬂected in both Sav monomers (designated SavA and SavB
hereafter), thus challenging a precise genetic ﬁne-tuning of the
ArM’s performance: it is hard to decipher which of the two
symmetry-related mutations (i.e., SavA or SavB) aﬀects (most)
the catalytic performance.
An additional challenge concerns the catalytic performance
as a function of cofactor occupancy within Sav. Indeed, some
ArMs display markedly diﬀerent catalytic performances as a
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function of cofactor:Sav ratio. Upon varying the [Cp*Ir(biot-p-
L)Cl]:Sav S112A ratio from one to four, the enantioselectivity
of the asymmetric transfer hydrogenase toward the salsolidine
precursor 1a erodes from 93% ee (R)-2a to 45% ee (R)-2a,
Figure 1c,d. In stark contrast, for [Cp*Ir(biot-p-L)Cl]:Sav
S112K, the enantioselectivity remains by-and-large constant,
irrespective of the above ratio (e.g., 70% ee (S)-2a vs 78% ee
(S)-2a upon varying the ratio from one to four).33 The
complications are exacerbated by the noncooperative binding
of biotinylated cofactors to Sav: adding 2 equiv of biotinylated
cofactor vs homotetrameric Sav aﬀords a Poisson distribution
of cofactor occupancy.38 With in vivo catalysis in mind,
whereby the [Sav] is unknown and highly variable, it is
desirable to achieve a precise control of ArM’s performance,
irrespective of the Sav:cofactor ratio.39−41 With these goals in
mind, we present herein our eﬀorts toward the engineering of a
single chain dimeric streptavidin (scdSav hereafter), enabling
the independent mutagenesis of the two neighboring Sav
subunits.
■ RESULTS AND DISCUSSION
Design of scdSav. Circular permutation strategies have
been applied to fuse two subunits of avidin while maintaining
high biotin-binding aﬃnity.42,43 Circularly permutated Sav has
also been reported but with a signiﬁcantly reduced aﬃnity to
biotin.44 Initially, we evaluated a similar approach to engineer
circularly permutated scdSav. However, these constructs
expressed poorly in E. coli (<1 mg L−1 in culture medium),
Figure 1. (a) Close-up view of the metal distribution of ArMs based on Sav. Homotetrameric Sav is displayed as surface, residues S112 and K121 of
adjacent Sav monomers forming the biotin-binding vestibule are shown as sticks and labeled; the metals from the biotinylated cofactors are
represented by spheres: Ir (yellow, PDB codes 6GMI, 6ESS, 6ESU, 4OKA, and 3PK2), Ru (raspberry, PDB codes 6FH8, 5F2B, 5IRA, 2QCB, and
2WPU), Cu (blue, PDB codes 5VKX, 5VL5, 5VL8, 5WBA, 5WBB, 5WBD, 6ANX, 5WBC, 5K67, 5K68, and 5L3Y), Pd (green, PDB code 5CSE)
and Rh (orange, PDB codes 4GJV and 4GJS). For clarity, only the metal ions present in the cofactors are shown (spheres, with only one metal per
Sav dimer displayed). (b) Cartoon representation of an ArM based on homotetrameric Sav with symmetry-related S112 and K121 in the proximity
of the biotinylated cofactor. (c) Close-up view of the X-ray structure of [Cp*Ir(biot-p-L)Cl]·Sav S112A (PDB code 3PK2) with all biotin-binding
sites occupied. As can be appreciated, severe steric clashes prevent the localization of adjacent cofactors to occupy the same orientation.31 The
homotetrameric Sav is displayed in surface representation and colored by protein chains. The cofactors are represented as stick models and the Ir-
atom as orange sphere; nitrogen, blue; oxygen, red; sulfur, yellow; chloride, green. (d) Michaelis−Menten kinetics of [Cp*Ir(biot-p-L)Cl]·Sav
S112A highlighting the marked inﬂuence of the cofactor loading on both the activity and the stereoselectivity of the corresponding ATHase.33 The
initial rates are displayed with respect to the concentration of iridium. [Sav] = 25 μM (corresponding to [biotin-binding sites] = 100 μM) was held
constant, varying the Ir/Sav ratio from 1.0 (blue data points) to 2.0 (red data points), 3.0 (green data points), and 4.0 (magenta data points). For
comparison, the initial rates for the free [Cp*Ir(biot-p-L)Cl] catalyst are displayed (50 μM, black data points). The positive ee values correspond
to (R)-salsolidine. The black solid lines correspond to the ﬁt obtained using the Michaelis−Menten or the Haldane equation. Reprinted in part with
permission from ref 33, Copyright 2014 ACS. (e) Design of scdSav relying on the linking of SavA and SavB via a peptide linker (red line) and
introducing a disulﬁde bond between two scdSavs (yellow line).
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hampering thorough characterization and practical implemen-
tation in biotechnology. We thus set out to fuse the C-terminus
of SavA with the N-terminus of SavB, Figure 1e. Inspection of
the X-ray structure of mature Sav (PDB code 2BC3)45 reveals
that the C- and N-termini are remote from each other in the
quaternary structure. To connect two Sav subunits, a 26 amino
acid linker was thus introduced. In addition, the following
points were taken into consideration in the design of scdSav:
(i) the DNA sequence homology of the two linked-Sav
subunits was minimized to facilitate mutagenesis of each Sav
subunit independently; (ii) as the H127 residue forms a π-
stacking interaction with its neighboring H127 residue, it was
mutated to H127C in the SavB to favor the formation of a
disulﬁde bond with an adjacent scdSav. This ensures the
precise assembly of two scdSavs into a single quaternary
structure (i.e., (scdSav)2) bearing one disulﬁde bond and one
π−π stacking interaction between the two remaining histidines
H127 present in the (scdSav)2 quaternary structure, Figure
1e.43,46 With these considerations in mind, scdSav was
engineered using a 26 aa linker between SavA and SavB, with
the H127C mutation in the SavB.
To evaluate the suitability of the scdSav design in the
context of ArMs, we selected the asymmetric transfer
hydrogenation of prochiral imines using [Cp*Ir(biot-p-L)Cl]
as a test bed (ATHase hereafter). In this context, the nature of
the amino acid at position 112 and 121 was repeatedly shown
to signiﬁcantly aﬀect the ATHase performance, both in terms
of activity and selectivity.31,33,47,48 In contrast to other ArMs
based on the biotin−streptavidin technology,9,23,24 the catalytic
performance of the evolved ATHases was shown to critically
depend on the cofactor:biotin-binding site ratio, Figure 1c,d.
Building on this knowledge, we engineered 33 scdSavs with
mutations at both of the S112 and K121 positions. The two
S112 positions were independently mutated to either alanine,
lysine or arginine. The two K121 were independently mutated
to an alanine residue or kept as a lysine. To simplify the
labeling of these variants, a 4-letter code is used hereafter: the
ﬁrst 2 letters code for residues 112 and 121 within the SavA
and the last 2 letters code for residues 112 and 121 in the SavB,
respectively. Accordingly, scdSav(SKSK) represents the “wild
type” scdSav, which includes the 26 aa linker and the H127C
mutation in the SavB, Figure 1e.
The scdSav(SASK) gene was synthesized and introduced on
the pRSFduet-1 plasmid. The other 32 scdSavs were generated
by site-directed mutagenesis using the above plasmid. All the
33 scdSavs were overexpressed in E. coli BL21(DE3) using an
autoinduction medium and puriﬁed by aﬃnity chromatography
on an iminobiotin-sepharose matrix (see SI Figure S1 for SDS-
PAGE analysis, Table S8 for MS data). For all 33 scdSav
variants, 10−50 mg of puriﬁed protein was obtained from 1 L
Scheme 1. Asymmetric Transfer Hydrogenation of Imines 1a−1e in the Presence of [Cp*Ir(biot-p-L)Cl]·scdSava
aThe size of the disk is proportional to the conversion and its color codes for the ee of the corresponding product. Reaction conditions: 10 mM
substrate, 25 μM [Cp*Ir(biot-p-L)Cl], 50 μM scdSav (= 100 μM biotin-binding sites), 0.6 M MOPS, 3 M formate, pH 7.0, 25 °C, 24 h.
Journal of the American Chemical Society Article
DOI: 10.1021/jacs.9b06923
J. Am. Chem. Soc. 2019, 141, 15869−15878
15871
of culture medium. SDS-PAGE analysis of the puriﬁed scdSavs
revealed the formation of (scdSav)2 (= tetramer of Sav) as the
major component, with higher oligomers of scdSav as the
minor byproducts (Figure S1). Importantly, all scdSavs
maintained their “four equivalents” binding capacity toward
biotin-4-ﬂuorescein (B4F).
ATHase Performance of ArMs Based on scdSav. Five
prochiral imines 1a−e were selected to evaluate the catalytic
performance of the engineered [Cp*Ir(biot-p-L)Cl]·scdSav.
Three isoquinoline derivatives (1a−1c), a 2H-pyrrole deriva-
tive (1d), and quinaldine (1e) were selected as the substrates
for the reduction, Scheme 1. With the exception of
isoquinoline 1a, these substrates have proven challenging to
reduce enantioselectively with ATHases. The results of the
ATHase screening for substrates 1a−e are summarized in
Scheme 1 (see also Table S1). While the free cofactor
[Cp*Ir(biot-p-L)Cl] aﬀords the corresponding racemic amines
2a−e in low conversion (1−18%), incorporation within WT
Sav leads to low to moderate conversion (9−68%)
accompanied by modest ee values (30−79%). Upon
substituting WT Sav by scdSav(SKSK), the resulting ATHase
activity by-and-large remains the same, both in terms of
conversion (14−70%) and enantioselectivity (42−79%).
Mutagenesis at positions 112 and 121 in both SavA and SavB
markedly altered the catalytic performance. To identify
important trends, the results were grouped and analyzed
according to the amino acids at each speciﬁc position (Figure
S2). For residue 112 in SavA, Ser and Ala clearly outperformed
Lys and Arg in terms of conversion for all substrates (Figure
S2a). The 112S/A in SavA is also more (R)-enantioselective for
isoquinoline derivatives (1a−1c) and (S)-enantioselective for
1e (Figure S2b). For residue 121 in SavA, Ala generally
improves the activity while largely maintaining the enantiose-
lectivity for 1a−1c and 1e (Figure S2c,d). The general eﬀects
of 112S/A and 121A in SavA suggest that they are contributing
to the binding of [Cp*Ir(biot-p-L)Cl] in a more productive
conformation, in line with a previous computational study of
ATHase based on Sav.33 On the other hand, no general trends
could be deduced for residues 112 and 121 in SavB (Figure
S2e−h). The substrate- and context-speciﬁc eﬀects of 112 and
121 in SavB suggest that they may contribute to interactions
with the substrate and thus ﬁne-tune the activity and
enantioselectivity. The best ATHases for each substrate are
discussed below. [Cp*Ir(biot-p-L)Cl]·scdSav(SARK) reduced
imine 1a to amine (R)-2a in 100% conversion (400 TON) and
96% ee, and imine 1b to amine (R)-2b in 99% conversion (398
TON) and 93% ee, respectively. In comparison with the
ATHases based on homotetrameric Sav, scdSav(SARK) is
similar to the benchmark Sav S112A for (R)-2a (full
conversion and 96% ee at 5 °C).31 For amine (R)-2b,
scdSav(SARK) is markedly more enantioselective than the
benchmark SavS112T (full conversion and 59% ee).49 Clearly,
the ﬁne-tuned scdSav(SARK) bearing 112S and 121A in SavA
and 112R and 121K in SavB outperforms all the homotetra-
meric Savs tested to date. For the reduction of the bulky
substrate 1c, none of the scdSavs exhibited high stereo-
selectivity (i.e., ee <70%). For the reduction of imine 1d,
[Cp*Ir(biot-p-L)Cl]·scdSav(SKAA) produced amine (R)-2d
in 90% conversion (360 TON) and 98% ee, outperforming the
best ATHase with homotetrameric Sav (68% conversion and
77% ee with WT Sav). Such high enantioselectivity (i.e., ee
≥95%) is challenging to achieve with ArMs. Again, scdSav-
(SKAA) bearing 112S and 121K in SavA and 112A and 121A
in SavB outperforms all homotetrameric Savs tested to date.
Quinaldine (1e) was only moderately reduced (conversion
<50%) by the ATHases under the experimental conditions.
Nevertheless, chiral amine (S)-2e was produced in 91% ee with
[Cp*Ir(biot-p-L)Cl]·scdSav(SARK). In recent years, a number
of imine reductase enzymes (IREDs) have been discovered
and applied to reduce many cyclic imines to chiral amines with
high enantioselectivity.50−52 More recently, several IREDs have
been found to catalyze reductive amination,53−55 i.e., ﬁrst
formation of imines and then reduction to amines, a
breakthrough in the enzymatic generation of amines. ATHases
have widely been used as a testbed for the development of
ArMs.12,31,33,41,48,49 In comparison to evolved IREDs recently
reported, ATHases typically display more modest catalytic
performances.
Engineering a Monovalent scdSav. In light of the high
activity and enantioselectivity for the imine reduction, we
selected the double mutant scdSav(SARK) to engineer a
monovalent scdSav to investigate the inﬂuence of a
neighboring cofactor on the catalytic performance of ATHases
based on scdSav. Binding of a second biotinylated cofactor in
the neighboring Sav subunit often leads to substantial erosion
in rate and enantioselectivity.33 To determine the biotin-
binding stoichiometry of scdSav, a biotin-4-ﬂuorescein (B4F
hereafter) titration was performed, relying on the intersection
of the two linear segments of the titration curve to determine
the binding stoichiometry.56 scdSav(SASK) and scdSav-
(SARK) bind 1.9 ± 0.1 and 2.0 ± 0.1 B4F per scdSav
respectively (Figure S3a,b). To generate a monovalent scdSav,
Figure 2. Saturation kinetic data for the reduction of imine 1a with [Cp*Ir(biot-p-L)Cl]·scdSav(SARK), scdSav(SARK)mv1, and
scdSav(SARK)mv2. The reaction rates are normalized to the concentration of [Cp*Ir(biot-p-L)Cl]. The [scdSav] was set at 50 μM and
[Cp*Ir(biot-p-L)Cl] was varied: 25 μM (blue circles), 50 μM (red squares), 75 μM (green triangles), 100 μM (purple triangles). For comparison,
the kinetic proﬁle of the free cofactor [Cp*Ir(biot-p-L)Cl] is displayed (50 μM, black crosses). Solid lines correspond to the ﬁtting to the Haldane
equation (ATHases) or Michaelis−Menten equation (free cofactor). Error bars represent ± standard deviation.
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while maintaining the overall topology within the biotin-
binding vestibule, two reported sets of mutations were
evaluated to knockout the biotin-binding capacity in SavB.
The following mutants were produced: scdSav(SARK) with
additional N23A/S27D in SavB (scdSav(SARK)mv1 hereafter)
and scdSav(SARK) with additional N23A/S27D/D128A in
SavB (scdSav(SARK)mv2 hereafter). The N23A/S27D and the
D128A mutants have been reported to disrupt key H-bonding
interactions between Sav and the ureido oxygen and ureido
nitrogen by Cantor57 and Salemme,58 respectively. Gratify-
ingly, BF4 titration of the resulting scdSav(SARK)mv1 and
scdSav(SARK)mv2 revealed the monovalent character of these
constructs: 1.1 ± 0.1 and 1.2 ± 0.1 biotin-binding sites were
determined for scdSav(SARK)mv1 and scdSav(SARK)mv2,
respectively (Figure S3c,d).
Saturation Kinetics of ATHases Based on scdSav. To
gain further insight into the catalytic eﬃciency of ATHases
based on scdSav, we determined the saturation kinetics and
enantioselectivity for the reduction of imine 1a to chiral amine
(R)-2a by [Cp*Ir(biot-p-L)Cl]·scdSav(SARK) and its two
monovalent variants with varying Ir:scdSav ratios. For all
measurements, the concentration of scdSav was kept at 50 μM,
whereas 25, 50, 75, 100 μM [Cp*Ir(biot-p-L)Cl] were used for
scdSav(SARK) (Ir:scdSav ratio = 0.5, 1.0, 1.5, 2.0 respec-
tively), and 25, 50 μM [Cp*Ir(biot-p-L)Cl] were used for the
monovalent Savs scdSav(SARK)mv1 and scdSav(SARK)mv2
(Ir:scdSav ratio = 0.5, 1.0 respectively). As summarized in
Figure 2 and Table 1, all the ATHases gave rise to high
enantioselectivities and pronounced rate-accelerations to aﬀord
up to 96% ee (R)-2a and up to a 10-fold higher kcat compared
to the free cofactor [Cp*Ir(biot-p-L)Cl]. For scdSav(SARK),
capable of binding up to two biotinylated cofactors per scdSav,
the reaction rate (kcat) markedly decreased and the
enantioselectivity was moderately reduced upon increasing
the Ir:scdSav beyond one. The erosion of rate and
enantioselectivity are in accordance with a previous study of
[Cp*Ir(biot-p-L)Cl]·Sav S112A,33 suggesting that the binding
of an additional [Cp*Ir(biot-p-L)Cl] in the neighboring Sav
subunit may cause a signiﬁcant conformational change of the
existing cofactor into a catalytically less favorable conforma-
tion.33 Because scdSav(SARK)mv1 and scdSav(SARK)mv2 are
monovalent, the biotinylated cofactor cannot bind to the
second Sav subunit. Thus, no detrimental eﬀects were
observed upon increasing the cofactor to protein ratio up to
full saturation. In addition, when Ir:scdSav ≤1, a higher
reaction rate was observed for monovalent scdSav (kcat =
16.0−23.6 min−1) than that of divalent scdSav (kcat = 10.0−
12.5 min−1) and previous homotetrameric Sav S112A (kcat =
11.4−14.1 min−1).33 The superiority of monovalent scdSav
may be traced back to the fact that all the bound cofactor
resides in a catalytically active conformation for the
monovalent scdSav. In contrast, and in light of the non-
cooperative binding of the cofactor within Sav, even at
Ir:scdSav ≤1, a portion of the cofactor [Cp*Ir(biot-p-L)Cl]
binds in an unproductive conformation, leading to an erosion
in rate.
Structural Characterization of scdSav ArMs by X-ray
Crystallography. To gain structural insight into the ATHases
based on the single chain dimeric streptavidin constructs, both
scdSav(SASK) and scdSav(SARK)mv2 were crystallized by
sitting drop vapor diﬀusion (2.5 μL 26 mg/mL (scdSav)2 in 10
mM sodium phosphate buﬀer with 150 mM NaCl, pH 7 was
mixed with precipitation buﬀer 2.5 μL, 2 M (NH4)2SO4, 0.1 M
Na-Acetate, pH 4). The resulting apo crystals were soaked with
excess [Cp*Ir(biot-p-L)Cl] (dissolved in DMSO). The soaked
yellow crystals were cryoprotected with 25% glycerol and ﬂash
frozen in liquid nitrogen. The structure was solved by
molecular replacement using the PDB structure 3PK2 as a
molecular model. Residual electron density in the Fo−Fc map
was observed in the biotin-binding pocket and in the biotin-
binding vestibule. Anomalous dispersion density was observed
in the biotin-binding vestibule. Modeling of cofactor [Cp*Ir-
(biot-p-L)Cl] into the electron density projected the iridium in
the position of the anomalous density peak. The X-ray
structures reveal, as anticipated, that [Cp*Ir(biot-p-L)Cl]·
scdSav(SASK) and [Cp*Ir(biot-p-L)Cl]·scdSav(SARK)mv2
diﬀer in their Ir:scdSav ratios. For the biological dimer of
scdSav(SASK) (i.e., (scdSav(SASK))2), both biotin-binding
sites present in the single chain dimer are occupied (i.e.,
amounting to four cofactors for the functional dimeric
assembly (scdSav)2), Figure 3a. In stark contrast, the biological
dimer of monovalent scdSav(SARK)mv2 (i.e., (scdSav-
(SARK)mv2)2) contains only one [Cp*Ir(biot-p-L)Cl]
cofactor per single chain dimer (i.e., two cofactors for the
functional dimeric assembly of (scdSav)2), Figure 3b (see
Figure S18 for the anomalous electron density of the iridium
atoms). To accommodate the two cofactors within the biotin-
binding vestibule of scdSav(SASK), the neighboring cofactors
are forced to adopt two diﬀerent conformations CI and CII,
each with a 50% occupancy and both in the (SIr)- conﬁguration
with a Cl− coordinated to Ir. Severe steric clashes prevent
neighboring cofactors from occupying two CI conformations
Table 1. Saturation Kinetic Parameters and Enantioselectivity for the Reduction of Imine 1a with ATHases Based on scdSava
protein [Cp*Ir(biot-p-L)Cl] (μM) (R)-2a ee (%)b kcat (min
−1)c Km (mM) Ki (mM)
no protein 50 1 1.3 ± 0.1 57 ± 20 n.a.d
scdSav(SARK) 25 94 10.0 ± 0.8 20 ± 5 687 ± 189
scdSav(SARK) 50 95 12.5 ± 1.2 32 ± 7 359 ± 79
scdSav(SARK) 75 87 4.6 ± 0.6 23 ± 8 474 ± 158
scdSav(SARK) 100 74 2.2 ± 0.3 38 ± 13 614 ± 285
scdSav(SARK)mv1 25 95 16.0 ± 1.7 31 ± 7 333 ± 77
scdSav(SARK)mv1 50 96 19.8 ± 2.9 36 ± 11 294 ± 89
scdSav(SARK)mv2 25 94 23.6 ± 3.0 52 ± 12 298 ± 74
scdSav(SARK)mv2 50 95 21.0 ± 2.7 42 ± 11 513 ± 168
aThe reaction conditions are described in Figure 2. The kinetic parameters were obtained using the Michaelis−Menten and Haldane equations for
the free cofactor and the ATHases, respectively. bThe ee values were determined after 48 h with [1a] = 25 mM. cThe kcat values are normalized to
the concentration of [Cp*Ir(biot-p-L)Cl]. dNot available. Error margins represent ± standard deviation resulting from two independent
experiments.
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simultaneously, Figure 3a. For [Cp*Ir(biot-p-L)Cl]·scdSav-
(SARK)mv2, only conformation CI is observed with 100%
occupancy with the (SIr)-conﬁguration and a Cl
− coordinated
to Ir (see Figure S19 for an overlay of the cofactors bound to
scdSav(SASK) and scdSav(SARK)mv2 and the 2Fo−Fc
electron density map of the cofactor). The RMSD of the
[Cp*Ir(biot-p-L)Cl] cofactor in conformation CI bound to
scdSav(SASK) and scdSav(SARK)mv2 is 0.576 Å (Table S7),
suggesting that this is the same conformation. Accordingly, we
hypothesize that the ﬁrst cofactor per scdSav adopts
conformation CI, for both scdSav(SASK) and scdSav(SARK)-
mv2. The second cofactor is forced to adopt conformation CII.
Conformation CI of cofactor [Cp*Ir(biot-p-L)Cl] observed
for scdSav is similar to the binding mode of monomeric
streptavidin Sav S112A (PDB: 3PK2)31 and Sav S112K (PDB:
4OKA)33 with an RMSD of 0.99−1.44 Å (see Table S7 and
Figure S20). Interestingly, the biggest RMSD deviation (1.51
Å, Table S7 and Figure S20) is observed for conformation CII
of cofactor [Cp*Ir(biot-p-L)Cl] in scdSav(SASK) compared
to Sav S112K. This suggests that CII resides in a shallower
potential energy well, provided by the protein, than
conformation CI.
As can be appreciated in Figure 3a, the protein environment
surrounding the two cofactor conformations CI and CII for
scdSav(SASK) is markedly diﬀerent (see also Figure S21 for
the stereo view of the environment). As predicted by Marećhal
and co-workers, the solvent-exposed CII conformation leads to
a decrease in activity and enantioselectivity, see Figure 2.33,59
As the catalytically less eﬃcient conformation CII is not
observed in [Cp*Ir(biot-p-L)Cl]·scdSav(SARK)mv2, the
corresponding ATHase leads to higher TONs and enantiose-
lectivity for most substrates, Table 2. As modeled for Sav
S112A- and Sav S112K-derived ATHases, we speculate that
the enantioselectivity is mainly determined by the absolute
conﬁguration at Ir.33,59 Accordingly, we believe that, as both CI
and CII conformations have the same absolute conﬁguration at
Figure 3. Structural characterization of scdSav(SASK) (a, PDB: 6S4Q) and scdSav(SARK)mv2 (b, PDB: 6S50) with bound [Cp*Ir(biot-p-L)Cl]
cofactor. The scdSav proteins are displayed as surface representation and colored by protein chains. The cofactors are represented as stick models
and the Ir-atom as orange sphere; nitrogen, blue; oxygen, red; sulfur, yellow. See Figure S21 for stereo view. (a) The two cofactor conformations
(CI and CII) of [Cp*Ir(biot-p-L)Cl] bound to each binding site are depicted. Both conformations CI and CII are occupied at 50%. Selected
distances between the two cofactors are highlighted in yellow dashes. (b) For monovalent scdSav(SARK)mv2, only one binding site per (scdSav)2
is occupied by [Cp*Ir(biot-p-L)Cl]. (c,d) The electron density maps (2Fo−Fc at 1 σ) of the residues stabilizing the interactions of a homodimeric
(scdSav(SARK)mv2)2: (c) the disulﬁde bond formed by the two C311-residues; (d) the π−π stacking interaction of the two H127-residues. The
protein is displayed in cartoon mode and colored by protein chain. The interacting amino acids are shown as sticks: nitrogen, blue; sulfur, yellow.
(e) Schematic illustration of the (nearly) statistical orientation of crystal packing of [Cp*Ir(biot-p-L)Cl]·scdSav(SARK)mv2, reﬂected in the
apparent occupation of both biotin-binding sites, albeit with partial occupancy. The orientation (scdSav)2 highlighted in blue in the crystal packing
leads to an apparent partial occupation of all four biotin-binding sites, although only the SavA site is eﬀectively occupied.
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Ir (i.e., SIr with a Cl
− coordinated to Ir), these preferentially
lead to the same enantioenriched amine, albeit with diﬀerent
levels of enantioselectivity.
Although the DNA sequence homology of the fused
subunits was minimized to simplify mutagenesis eﬀorts, the
amino acid sequence of both subunits is nearly identical: the
size, the fold, and the corresponding electron density observed
for each subunit of the scdSav are very similar. Accordingly, in
the crystal packing, each tetramer can occupy two orientations
leading to a mixed electron density. Nonetheless, we observed
a preferential orientation of scdSav(SASK) and scdSav-
(SARK)mv2 in the crystals resulting in diﬀerences for the
electron density of N23A/S27D/H127C/D128A and the
cofactor binding of scdSav(SARK)mv2. We thus assigned the
amino acid sequence according to the dominant electron
density observed. The electron density map (2Fo−Fc) of the
H127 and C311 stabilizing the interaction of the homodimeric
(scdSav(SARK)mv2)2 is shown in Figure 3c, d. The statistical
distribution of the tetramer orientation and the resulting mixed
structure is depicted in Figure 3e. The 26 amino acid linker
between the two subunits could not be modeled as no electron
density was observed for these amino acids.
Reaction Optimization and Preparative Scale Syn-
thesis. Having identiﬁed the best (scdSav)2 scaﬀolds for the
reduction of imines, we sought to optimize the conditions for
the ATHases. For this purpose, the eﬀect of temperature, pH,
and substrate concentration were evaluated. For the asym-
metric reduction of imine 1a, pH = 7.0 proved best both in
terms of conversion and enantioselectivity (Figure S5). Upon
increasing the temperature from 25 to 50 °C, higher turnover
frequencies (TOF) and TONs were observed, at the cost of a
slightly eroded ee (Table 2 and Figure S6). Next, the catalytic
potential of [Cp*Ir(biot-p-L)Cl]·scdSav(SARK) and both its
monovalent isoforms were tested (Table 2). At 50 °C and with
[Cp*Ir(biot-p-L)Cl] (5 μM), scdSav(SARK) (5 μM) and
substrate 1a (100 mM), amine (R)-2a is produced in 78%
conversion (TON = 15 600) and 86% ee. With [Cp*Ir(biot-p-
L)Cl]·scdSav(SARK)mv2, the conversion and the enantiose-
lectivity increases to 88% (TON = 17 700) and 90% ee (R)-2a.
This TON is signiﬁcantly higher than that of [Cp*Ir(biot-p-
L)Cl]·Sav S112A (TON = 4000).31 High substrate loading is
often challenging for ATHases. Indeed, for the [Cp*Ir(biot-p-
L)Cl]·scdSav(SARK) isoforms, we determined substrate
inhibition (Ki = 294−687 mM, Table 1). To circumvent this
challenge, we applied a slow feed of substrate 1a. To our
delight, substrate 1a (500 mM) was reduced to amine (R)-2a
in 95% conversion and 87% ee with [Cp*Ir(biot-p-L)Cl]·
scdSav(SARK)mv2 (50 μM) (Table 2, and Figure S7 for the
time course). This corresponds to a product concentration of
98.5 g/L, which is similar to the current record of IRED (103.5
g/L) for the same type of reaction.55 A preparative-scale
experiment (reaction volume 10 mL) was carried out with
substrate 1a (200 mM) and [Cp*Ir(biot-p-L)Cl]·scdSav-
(SARK)mv1 (50 μM) in a conical ﬂask: 408.2 mg of amine
(R)-2a was isolated in 91% ee and 98.5% yield (see Figure S8
for the time course). The same preparative reaction was also
performed with [Cp*Ir(biot-p-L)Cl]·scdSav(SARK)mv2 (50
μM) and 399.3 mg of amine (R)-2a was isolated in 92% ee and
96.3% yield (Figure S8). Importantly, essentially pure (R)-
salsolidine 2a could be obtained following a simple extraction
procedure (>95% purity by 1H NMR, see Figure S16 and S17).
The asymmetric reduction of other prochiral imines 1b, 1d,
and 1e was also investigated, Scheme 2. By evaluating diﬀerent
loading of 1b and reaction temperatures (Table S2), we found
that imine 1b (100 mM) was quantitatively reduced to amine
(R)-2b in 91% ee with [Cp*Ir(biot-p-L)Cl]·scdSav(SARK)-
Table 2. Optimization of the Reduction of Dihydroisoquinoline 1a with ATHases Based on scdSava
protein [Cp*Ir(biot-p-L)Cl] (μM) 1a conc. (mM) temp. (°C) conv. (%) (R)-2a ee (%) TON
scdSav(SARK) 5 10 25 95 96 1910
scdSav(SARK) 5 50 25 73 92 7320
scdSav(SARK) 5 100 25 53 90 10 700
scdSav(SARK) 5 100 50 78 86 15 600
scdSav(SARK)mv1 5 100 50 84 89 16 900
scdSav(SARK)mv2 5 100 50 88 90 17 700
scdSav(SARK) 50 500b 50 86 85 8630
scdSav(SARK)mv1 50 500b 50 95 87 9540
scdSav(SARK)mv2 50 500b 50 95 87 9510
aReaction conditions: 10−500 mM substrate, 5−50 μM [Cp*Ir(biot-p-L)Cl], 5−50 μM scdSav (= concentration of [Cp*Ir(biot-p-L)Cl]), 0.6 M
MOPS, 3 M formate, pH 7.0, 25−50 °C, 48 h. b1a (100 mM aliquots) was fed for ﬁve consecutive times at t = 0, 2, 5, 10, and 20 h.
Scheme 2. Optimized Conditions for the Reduction of
Prochiral Imines 1b, 1d, and 1e with ATHases Based on
scdSav Variants
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mv2 (50 μM), corresponding to a TON of 2000. Similarly,
imine 1d (100 mM) was reduced to amine (R)-2d in 99%
conversion and 96% ee with [Cp*Ir(biot-p-L)Cl]·scdSav-
(SKAA) (50 μM), corresponding to a TON of 1980 (Table
S3). Quinaldine (1e) proved challenging to reduce: only 24%
conversion to (S)-2e was obtained with [Cp*Ir(biot-p-L)Cl]·
scdSav(SARK) (Scheme 1). Upon increasing the reaction
temperature to 50 °C and relying on scdSav(SARK)mv2
(Table S4), 98% conversion (TON = 195) and 91% ee (S)-2e
could be achieved with 50 μM [Cp*Ir(biot-p-L)Cl]·scdSav-
(SARK)mv2.
■ CONCLUSION AND OUTLOOK
With the aims of expanding the genetic optimization potential
as well as resolving the issue related to multiple cofactor
binding within the biotin-binding vestibule in ArMs based on
the biotin−streptavidin technology, we engineered a single-
chain dimeric streptavidin. As both SavA 112 and SavB 112
residues as well as SavA 121 and SavB 121 lie in the immediate
proximity of the biotinylated metal moiety (Figure 1), the
possibility of varying these four critical residues individually (to
potentially generate 204 = 160 000 scdSav mutants) signiﬁ-
cantly expands the genetic diversity of ArMs based on
scdSav.60−62 The potential of this strategy was highlighted by
evaluating the ATHase activity of 33 diﬀerent scdSavs toward
challenging substrates 1a−e. Gratifyingly, the resulting
ATHases outperformed homotetrameric Sav-based ATHases,
both in terms of activity (e.g., TON) and selectivity. Further
improvements were observed in the presence of monovalent
scdSav(SARK)mv1 and scdSav(SARK)mv2. Enzyme kinetics
revealed that the monovalent scdSavs outperform the related
divalent scdSav for the reduction of substrates 1a, 1b, and 1e,
as the interference of neighboring cofactors is lifted, as
highlighted in the X-ray structure of [Cp*Ir(biot-p-L)Cl]·
scdSav(SASK) and [Cp*Ir(biot-p-L)Cl]·scdSav(SARK)mv2.
The practicality of [Cp*Ir(biot-p-L)Cl]·scdSav(SARK)mv2
was illustrated for the reduction of imine [1a] = 500 mM to
aﬀord salsolidine (R)-2a in 90% ee and >17 000 TONs. In
view of the high recombinant Sav production yields obtained
in fed-batch mode (e.g., > 8 g/L soluble homotetrameric
Sav),37 we hope that these ﬁndings will contribute to large
scale applications of this technology. With in vivo catalysis in
mind,39−41,63−65 the use of a monovalent scdSav may prove
versatile as the catalytic performance of the ArMs is
independent of cofactor:Sav ratios. This may also prove useful
in other advanced biotechnological applications.66
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Schirmer, T.; Ward, T. R.; Marećhal, J.-D. Structural, Kinetic, and
Docking Studies of Artificial Imine Reductases Based on Biotin-
Streptavidin Technology: An Induced Lock-and-Key Hypothesis. J.
Am. Chem. Soc. 2014, 136, 15676−15683.
(34) Cotelle, Y.; Lebrun, V.; Sakai, N.; Ward, T. R.; Matile, S.
Anion-π enzymes. ACS Cent. Sci. 2016, 2, 388−393.
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(49) Köhler, V.; Wilson, Y. M.; Dürrenberger, M.; Ghislieri, D.;
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